OncoMatch/Clinical Trials/Multiple Myeloma (MM)
Multiple Myeloma (MM) Clinical Trials
OncoMatch filters Multiple Myeloma (MM) trials by the molecular markers that determine eligibility — KRAS, NRAS, BRAF, TP53, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Multiple Myeloma (MM) trials
These are the molecular markers most commonly required or evaluated in Multiple Myeloma (MM) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Multiple Myeloma (MM) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme LLC
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
European Myeloma Network B.V.
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Pfizer
How OncoMatch finds Multiple Myeloma (MM) trials for you
AI reads the protocol
Every Multiple Myeloma (MM) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Multiple Myeloma (MM) and mark your biomarker results — KRAS, NRAS, BRAF — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.